Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/5/2025

Cardiovascular Side Effects of Capecitabine

Primary Cardiovascular Manifestations

  • The American College of Cardiology notes that capecitabine causes cardiovascular toxicity in approximately 3-9% of patients, with myocardial ischemia, arrhythmias, and coronary vasospasm being the primary manifestations, and patients with pre-existing cardiac disease face substantially elevated risk 1
  • Capecitabine induces symptomatic ischemic ECG changes in 5.2% of patients without prior coronary artery disease, with the incidence ranging from 3-9% across studies 1
  • The mechanism involves coronary vasospasm as the primary pathophysiologic driver, with ECG changes documented in 68% of patients experiencing cardiac events 1, 2
  • Cardiac biomarker elevations occur in only 43% of cases with ischemic ECG changes, meaning normal troponins do not exclude capecitabine cardiotoxicity 1

Cardiac Arrhythmias

  • The European Society of Cardiology notes that capecitabine causes multiple arrhythmia types including atrial fibrillation, supraventricular tachycardia, ventricular arrhythmias, bradycardia, and conduction disturbances 3, 4
  • Bradycardia and atrioventricular block are specifically listed as capecitabine-associated arrhythmias by the European Society of Cardiology 3

High-Risk Patient Populations

  • Patients with prior coronary vasospasm should generally avoid capecitabine in favor of alternative regimens whenever oncologically feasible, as they face substantially elevated risk for recurrent life-threatening events 2, 7
  • Prior mediastinal radiation accelerates drug-related coronary damage 1

Critical Management Principles

  • The American College of Cardiology suggests that alternative regimens not containing fluoropyrimidines are preferred over rechallenge with capecitabine 2
  • Serial ECGs during treatment are recommended by the American College of Cardiology 2
  • Frequent vital signs monitoring during treatment cycles is recommended 8

Mortality Risk

  • Overall mortality from capecitabine cardiotoxicity ranges from 2.2% to 13% across studies 1
  • Sudden cardiac death has been reported, likely related to ischemia and coronary vasospasm 3

Common Clinical Pitfalls

  • Do not assume normal coronary angiography excludes capecitabine cardiotoxicity, as endothelial injury and small vessel thrombosis may be undetectable by angiography 2